Springer Protocols: Abstract: 11. Identification of Tumor-Associated Autoantigens With SEREX

11. Identification of Tumor-Associated Autoantigens With SEREX

By: Özlem Türeci³, Dirk Usener⁴, Sandra Schneider⁴, Ugur Sahin⁵

Abstract

Full Text

Download PDF (146K)

Serological analysis of tumor antigens by recombinant cDNA expression cloning (SEREX) allows the systematic cloning of tumor antigens recognized by the spontaneous autoantibody repertoire of cancer patients. For SEREX, cDNA expression libraries are constructed from fresh tumor specimens, packaged into λ-phage vectors, and expressed recombinantly in Es-cherichia coli. Recombinant proteins expressed during the lytic infection of bacteria are transferred onto nitrocellulose membranes to be probed with diluted autologous patient serum for identification of clones reactive with high-titered IgG antibodies. This chapter describes the SEREX technology in detail.

Affiliation(s): (3) Department of Internal Medicine, Johannes Gutenberg- University, Mainz, Germany
(4) Research and Development, Ganymed Pharmaceuticals, Mainz, Germany
(5) Department of Internal Medicine, Johannes Gutenberg-University, Mainz, Germany

Book Title: Adoptive Immunotherapy: Methods and Protocols

Series: Methods in Molecular Medicine | Volume: 109 | Pub. Date: Nov-30-2004 | Page Range: 137-154 | DOI: 10.1385/1-59259-862-5:137

Subject: Immunology

Key Words: Tumor antigens - expression screening - λ-phage libraries - autoantibodies

References

Download References

1.	Boon, T., Cerottini, J. C., van den Eynde, B., van der Bruggen, P., and van Pel, A. (1994) Tumor antigens recognized by T-lymphocytes. Annu. Rev. Immunol. 12, 337–366.

2.	van der Bruggen, P., Traversari, C., Chomez, P., et al. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643–1647.

3.	Hartley, S. B., Booke, M. P., Fulcher, D. A., et al. (1993) Elimination of self reactive B lymphocytes proceeds in two stages: arrested development and cell death. Cell 72,325–335.

4.	Sahin, U., Türeci, O., Schmitt, H., et al. (1995) Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA 92, 11,810–11,813.

5.	Sahin, U., Türeci, O., and Pfreundschuh, M. (1997) Serological identification of human tumor antigens. Curr. Opin. Immunol. 9, 709–716.

6.	Türeci, O., Sahin, U., and Pfreundschuh, M. (1997) Serological analysis of human tumor antigens: Molecular definition and implications. Mol. Med. Today 3, 342–349.

7.	Boon, T. and Old, L. J. (1997) Cancer tumor antigens. Curr. Opin. Immunol. 9, 681–683.

8.	Jongeneel, V. (2001) Towards a cancer immunome database. Cancer Immun. 1, 3.

9.	Zarour, H. M., Maillere, B., Brusic, V., et al. (2002) NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1-and Th2-type tumor-reactive CD4+T cells. Cancer Res. 62, 213–218.

10.	Zeng, G., Li, Y., El-Gamil, M., et al. (2002) Generation of NY-ESO-1-specific CD4+and CD8⁺T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res. 62, 3630–3635.

11.	Jager, E., Gnjatic, S., Nagata, Y., et al. (2000) Induction of primary NY-ESO-1 immunity: CD8⁺T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+cancers. Proc. Natl. Acad. Sci. USA 97, 12,198–12,203.

12.	Old, L. J. and Chen, Y. T. (1998) New paths in human cancer serology. J. Exp. Med. 187, 1163–1167.

13.	Maniatis, T., Sambrook, J., and Fritsch, E. F., eds. (1989) Molecular Cloning: A Laboratory Manual. 2nd Ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp.7.11–7.12.

14.	Chomczynski, P. and Sacchi, N. (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156–159.

15.	Krause, P., Türeci, Ö., Micke, P., Buhl, R., Huber, C., and Sahin, U. (2003) SeroGRID: An improved method for the rapid selection of antigens with disease related immunoge-nicity. J. Immunol. Methods 283, 261–267.

16.	Türeci, Ö., Schmitt, H., Fadle, N., Pfreundschuh, M., and Sahin, U. (1997) Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin’s disease. J. Biol. Chem. 272 6416–6422.

17.	Diatchenko, L., Lukyanov, S., Lau, Y. F., and Siebert, P. D. (1999) Suppression subtrac-tive hybridisation: A versatile method for identifying differentially expressed genes. Methods Enzymol. 303, 349–380.

18.	Türeci O., Sahin, U., Zwick, C., Neumann, F., and Pfreundschuh, M. (1999) Exploitation of the antibody repertoire of cancer patients for the identification of human tumor antigens. Hybridoma 18, 23–28.

19.	Stockert, E., Jäger, E., Chen, Y. T., et al. (1998) A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 187, 1349–1354.

20.	Lagarkova, M. A., Koroleva, E. P., Kuprash, D. V., et al. (2003) Evaluation of humoral response to tumor antigens using recombinant expression-based serological mini-arrays (SMARTA). Immunol. Lett. 85, 71–74.

21.	Scanlan, M. J., Welt, S., Gordon, C. M., et al. (2002) Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res. 62,4041–047.

22.	Türeci, Ö., Luxemburger, U., Heinen, H., et al. (2004) CrELISA: A fast and robust enzyme linked immuno sorbent assay bypassing the need for purification of recombinant protein. J. Immunol. Methods, in press.

23.	Türeci, Ö., Sahin, U., Zwick, N., Neumann, F., and Pfreundschuh, M., (1999) Identification of human tumor antigens using the antibody repertoire of cancer patients. Gann Monograph Cancer Res. 48, 93–101.

Comments (Loading...)

Post comment/View all comments